SCHEMBL4843951

SCHEMBL4843951

COCCC1CN(C2=Nc3ccc(F)cc3Nc3sc(C(C)C)cc32)CCN1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 5/20 0.37
HRH1 P35367 5/20 0.37
DRD2 P14416 5/20 0.37
CHRM2 P08172 4/20 0.37
CHRM4 P08173 4/20 0.37
CHRM5 P08912 4/20 0.37
CHRM3 P20309 4/20 0.37
DRD1 P21728 4/20 0.37
ADRA1D P25100 4/20 0.37
HTR2A P28223 4/20 0.37
HTR2C P28335 4/20 0.37
ADRA1A P35348 4/20 0.37
ADRA1B P35368 4/20 0.37
HTR2B P41595 4/20 0.37
ADRA2A P08913 3/20 0.37
ADRA2B P18089 3/20 0.37
ADRA2C P18825 3/20 0.37
KCNH2 Q12809 3/20 0.37
HTR3E A5X5Y0 1/20 0.33
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4843943 1.00 CHRM1 (0.37) CHRM1HRH1DRD2CHRM2CHRM4
SCHEMBL4841076 0.89 CHRM1 (0.48) CHRM1HRH1DRD2CHRM2CHRM4
SCHEMBL4837066 0.89 CHRM1 (0.48) CHRM1HRH1DRD2CHRM2CHRM4
SCHEMBL4837056 0.89 CHRM1 (0.48) CHRM1HRH1DRD2CHRM2CHRM4
SCHEMBL4841062 0.89 CHRM1 (0.48) CHRM1HRH1DRD2CHRM2CHRM4
Hydrochloric Acid SCHEMBL4845657 0.89 CHRM1 (0.48) CHRM1HRH1DRD2CHRM2CHRM4
Hydrochloric Acid SCHEMBL4845663 0.89 CHRM1 (0.48) CHRM1HRH1DRD2CHRM2CHRM4
SCHEMBL4835800 0.88 CHRM1 (0.39) CHRM1HRH1DRD2CHRM2CHRM4
SCHEMBL4835792 0.88 CHRM1 (0.39) CHRM1HRH1DRD2CHRM2CHRM4
SCHEMBL14156738 0.86 CHRM1 (0.39) CHRM1HRH1DRD2CHRM2CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1546134-A1 PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES ELI LILLY AND COMPANY (US) 2005-06-29 EP claimed
WO-2004014895-A1 PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES ELI LILLY AND COMPANY (US) 2004-02-19 WO claimed
US-7384934-B2 Piperazine substituted aryl benzodiazepines ELI LILLY AND COMPANY (US) 2008-06-10 US disclosed
EP-1546134-B1 PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES LILLY CO ELI (US) 2007-05-02 EP disclosed
US-20060084643-A1 Piperazine substituted aryl benzodiazepines ELI LILLY AND COMPANY 2006-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084643-A1 Piperazine substituted aryl benzodiazepines GABBR1, GABBR2, GABRA5 CHRM1 302/4885HRH1 570/4885DRD2 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.